(Avibactam sodium + aztreonam) is under clinical development by AbbVie and currently in Phase III for Bacterial Pneumonia. According to GlobalData, Phase III drugs for Bacterial Pneumonia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Avibactam sodium + aztreonam)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Avibactam sodium + aztreonam) overview
Avibactam sodium and Aztreonam (Emblaveo) is a fixed dose combination acts as antibacterial agents. It is formulated as concentrated solution for intravenous route of administration. Emblaveo is indicated for the treatment of hospital-acquired pneumonia, ventilator-acquired pneumonia, complicated intra-abdominal infections, complicated urinary tract infections, pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
PF-06947387 (aztreonam in combination with avibactam) is under development for the treatment of serious gram-negative bacterial infections caused by multiple-drug resistant pathogens producing metallo-beta-lactamases such as hospital-acquired pneumonia, ventilator-acquired pneumonia, complicated intra-abdominal infections, complicated urinary tract infections, pyelonephritis, peritonitis and bacterial pneumonia. The combination therapy is administered intravenously as a solution. It is a new molecular entity.
AbbVie overview
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, healthcare facilities, government agencies, specialty pharmacies, and independent retailers. The company has operations in the Americas, Asia-Pacific, Europe, the Middle East and Africa. AbbVie is headquartered in North Chicago, Illinois, the US.
For a complete picture of (Avibactam sodium + aztreonam)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
